New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency

Area of Science:

• Biochemistry
• Neuroscience
• Toxicology

Background:

• Botulinum neurotoxins (BoNTs) are potent toxins used therapeutically for neuromuscular disorders.
• Current commercial BoNT treatments primarily use serotypes A and B; serotype F has limited use due to its short duration.
• The BoNT/F7 subtype exhibits unique light chain properties, including extended substrate interaction and superior catalytic activity.

Purpose of the Study:

• To engineer and characterize a modified Botulinum neurotoxin type F (BoNT/F7-1) chimera.
• To evaluate the potency and safety profile of the engineered BoNT/F7-1.
• To explore the therapeutic potential of the modified BoNT/F7-1 for unmet medical needs.

Main Methods:

• Engineered a chimeric BoNT/F7 neurotoxin (mrBoNT/F7-1) by incorporating the activation loop from BoNT/F1.
• Expressed and purified the recombinant mrBoNT/F7-1.
• Assessed the in vitro and in vivo activity, potency, and safety of mrBoNT/F7-1.

Main Results:

• The engineered mrBoNT/F7-1 demonstrated successful post-translational activation.
• mrBoNT/F7-1 exhibited enhanced potency compared to native and recombinant BoNT/F1.
• The safety profile of mrBoNT/F7-1 was comparable to BoNT/F1.

Conclusions:

• The modified recombinant BoNT/F7-1 is a potent neurotoxin with a favorable safety profile.
• This engineered toxin holds promise for developing novel therapeutics for neuromuscular conditions.
• mrBoNT/F7-1 represents a potential advancement in BoNT-based therapies.